Serial Intravitreal Bevacizumab Injections Slow the Progression of Radiation Maculopathy Following Iodine-125 Plaque Radiotherapy

Table 3: Using fluorescein angiography to predict response to intravitreal bevacizumab (IVB).

	FA Results	Change in Visual Acuity after Initial Three IVB Injections	Change in Visual Acuity at Last Follow-Up	Days Since First Injection
Patient 1	Macular Leakage	-0.2	-0.2	62
Patient 2	Macular Leakage	-0.1	-0.1	373
Patient 3	Macular Leakage	-0.1	0	331
Patient 4	Macular Leakage	0.2	0	263
Patient 5	Macular Leakage	-0.9	-0.3	1056
	Average	-0.22	-0.12	417
Patient 6	No Leakage	0.4	1.6	924
Patient 7	No Leakage	0.6	0.7	1304
Patient 8	No Leakage	0.1	0	338
Patient 9	No Leakage	0.3	2.5	283
Patient 10	No Leakage	-0.1	0.2	277
Patient 11	No Leakage	-0.1	0.8	1049
	Average	0.2	0.97	695.8

Patients with late-phase macular leakage on fluorescein angiography at the time of initial intravitreal bevacizumab injection had better visual outcomes than patients who did not have any leakage in the macula.